
On 17 November 2026, SELLAS Life Sciences announced topline results from REGAL, a randomized Phase 3 trial of galinpepimut-S, an off-the-shelf vaccine targeting the WT1 protein, in adults with acute myeloid leukemia (AML) in remission. The company reports median overall survival of 24.0 months against 14.7 months with best available treatment, a hazard ratio of 0.59 and a two-sided p-value of 0.035. The data are topline, not peer reviewed, and no approval has been granted.
What happened
SELLAS Life Sciences Group (NASDAQ: SLS) released the REGAL results on 17 November 2026 through a company press release distributed by GlobeNewswire. The trial, registered as NCT04229979, is described by the company as a global, randomized, open-label, registrational Phase 3 trial. It enrolled 126 patients who were randomized 1:1 to galinpepimut-S (GPS) as maintenance monotherapy or to the investigator’s choice of best available treatment.
According to the company, the primary endpoint of overall survival was met. Median overall survival was 24.0 months in the GPS arm and 14.7 months in the control arm, a gap of about nine months. The hazard ratio was 0.59, which the company describes as a 41% reduction in the risk of death, with a two-sided p-value of 0.035. The analysis was run after the pre-specified 80 deaths, as set out in the statistical analysis plan.
The company says GPS was generally well tolerated and consistent with prior clinical experience, with no new safety signals. Treatment-related adverse events were mostly grade 1 or 2, most commonly local injection-site reactions. SELLAS also reports that prognostic factors were well balanced between the arms and that few patients went on to a stem cell transplant, split evenly between the arms.
Key details of the REGAL trial
The table sets out the design as described in the company’s announcement and the public registry record.
| Item | Detail | Source |
|---|---|---|
| Trial | REGAL, NCT04229979, randomized, open-label, parallel group, Phase 3 | SELLAS release; ClinicalTrials.gov |
| Sponsor | Sellas Life Sciences Group, with PPD Development, LP listed as a collaborator | ClinicalTrials.gov |
| Population | Adults with AML in second or later complete remission, or complete remission with insufficient platelet recovery, after second- or later-line salvage therapy, who are ineligible for or unable to undergo allogeneic stem cell transplantation | SELLAS release |
| Comparator | Investigator’s choice of best available treatment: observation, a hypomethylating agent, venetoclax and/or low-dose cytarabine | SELLAS release |
| Participants | 126 randomized 1:1 as reported by the company; the registry record lists an actual enrollment of 127 | SELLAS release; ClinicalTrials.gov |
| Primary endpoint | Overall survival, defined in the registry as the interval between randomization and death from any cause | ClinicalTrials.gov |
| Result | Median 24.0 vs 14.7 months; hazard ratio 0.59; two-sided p = 0.035; 80 deaths | SELLAS release; BioPharm International |
The registry record shows the trial started on 8 February 2021 and was listed as active, not recruiting, with a status last verified in September 2025 and an estimated study completion in December 2026.
Background and context
Galinpepimut-S is a peptide vaccine that targets WT1, a protein that Memorial Sloan Kettering Cancer Center (MSK) says is found in the cancer cells of more than 95% of people with AML. MSK describes the vaccine as built from synthetic peptides, as off-the-shelf rather than personalized, and as intended to train the immune system to attack residual leukemia cells that treatment may not detect and that can lead to relapse. The vaccine was invented by David A. Scheinberg, MD, PhD, at MSK, and was licensed to SELLAS.
BioPharm International reports that an earlier Phase 2 trial of 22 AML patients found a CD4 or CD8 immune response in 9 of 14 patients tested, or 64%, with grade 1 or 2 injection-site reactions in 46%. In the REGAL population, patients in second or later remission who cannot undergo transplant, the REGAL steering committee says patients face poor outcomes and need new approaches.
The company’s announcement quotes Angelos Stergiou, MD, ScD h.c., SELLAS president and chief executive, calling the results a defining milestone for the company. The REGAL Study Steering Committee, named in the release as Hagop M. Kantarjian, MD, of MD Anderson, Javier Pinilla-Ibarz, MD, PhD, of Moffitt, and M. Yair Levy, MD, of Texas Oncology-Baylor, said GPS has the potential to redefine the treatment paradigm in AML maintenance therapy.
Reaction and independent reporting
MSK published its own account on 17 November 2026. Dr. Scheinberg is quoted there saying the data bring the field closer to having the first off-the-shelf vaccine for AML patients. MSK discloses that the institution and Dr. Scheinberg have financial interests related to SELLAS, and the SELLAS release adds that Dr. Pinilla-Ibarz also has such interests.
Trade coverage by BioPharm International reproduces the company figures and adds its own cautions: the results are topline and not peer reviewed, the announcement gives no confidence interval for the hazard ratio, the trial was open-label, the control arm combined several different approaches including observation, and the sample of 126 patients is small. Drug Development and Commercialization reports the same figures and notes that the control group was heterogeneous and that secondary endpoints are still being analyzed. Both reports draw their numbers from the company release.
What it means for researchers, universities and research offices
For clinical researchers in AML and immuno-oncology, the announcement is a topline survival signal from a randomized trial, but the evidence is not yet in a form that can be critiqued in detail. The open-label design means patients and clinicians knew who received the vaccine; the comparison of open-label and double-blind designs explains why that matters for endpoints that rely on investigator judgement, although overall survival is a harder endpoint than most. Anyone reviewing the full dataset will want to see how the hazard ratio was estimated, as described in the guide to the Cox proportional hazards model, together with its confidence interval.
For research offices and institutional compliance teams, three points are concrete. First, the registry record and the announcement differ on enrollment, 127 in the registry as last updated against 126 reported by the company, so offices tracking sponsor-reported outcomes should reconcile them against the full results once published. The ClinicalTrials.gov entry and the guide to clinical trial registration and reporting compliance explain registration and reporting obligations. Second, MSK, an academic cancer centre, and its inventor disclose financial interests in the sponsor, which is the kind of institutional and individual interest that conflict-of-interest offices manage around licensed technology. Third, the vaccine was developed from academic discovery and licensed to a company, so technology transfer offices can point to a case where an institutional licence has now reached a pivotal trial readout.
The result does not make GPS an available treatment. It is an investigational product, and the company itself says the FDA may not agree with its analyses or with an expedited path.
What happens next
SELLAS says it plans to meet with the FDA to discuss an accelerated filing strategy and is targeting a Biologics License Application submission in the first half of 2027. Full secondary-endpoint analyses and additional pre-specified analyses are underway, including leukemia-free survival, measurable residual disease and T-cell response dynamics. The company says it will present the results at an upcoming major medical conference and submit them for peer-reviewed publication, without naming a venue or date. The company also states that final results may differ from the topline data. The registry record shows an estimated study completion date of December 2026.
Sources
- SELLAS Life Sciences: Positive pivotal Phase 3 REGAL trial data for galinpepimut-S, 17 November 2026
- ClinicalTrials.gov: NCT04229979, Galinpepimut-S Versus Investigator’s Choice of Best Available Therapy for Maintenance in AML CR2/CRp2, record last updated 1 October 2025
- Memorial Sloan Kettering Cancer Center: Vaccine Improves Survival in People with Acute Myeloid Leukemia (AML), 17 November 2026
- BioPharm International: SELLAS cancer vaccine galinpepimut-S overall survival, Phase 3 REGAL AML, 17 November 2026
- Drug Development and Commercialization: SELLAS Reports Positive Phase 3 Results for AML Vaccine, Plans FDA Discussions in 2027







